tags

Safety Testing
China
Interpretation on Matters Concerning Cosmetic Registration and Filing by China NMPA

At a Glance: On July 29, 2026, China’s NMPA released new measures optimizing cosmetic registration and filing to enhance efficiency and stimulate industry innovation. Key reforms include exempting market-sale proof for foreign first-launch products, reducing animal testing, shifting ingredient safety files to enterprise archiving, allowing shared safety data for similar formulas, simplifying cross-border site transfers, and expanding flexible efficacy evaluation methods.

China Cosmetic Testing Requirements: CMA, CNAS, and ISO 17025 Explained

Not all cosmetic test reports are created equal: some are rejected by regulators, and some aren’t internationally recognized. Choosing the wrong laboratory can delay your product launch or even block market entry entirely. This article explains the differences between CMA, CNAS, and ISO 17025 accreditation, why they matter for cosmetic testing in China, and how to select the right lab for regulatory compliance.

Summary Report on Cosmetic Supervision and Sampling Inspection in China – April 2026

In April 2026, China's National Medical Products Administration (NMPA), the Guangdong Provincial Medical Products Administration, and the Sichuan Provincial Medical Products Administration successively issued announcements on cosmetic supervision and sampling inspection. A total of 103 batches of cosmetics were found non-compliant, and 47 batches were detected with prohibited ingredients.